President's Page: New ACC/AHA Prevention Guidelines: Building a Bridge to Even Stronger Guideline Collaborations  by Harold, John Gordon & Jessup, Mariell
Journal of the American College of Cardiology Vol. 62, No. 22, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.10.044FROM THE ACCPresident’s Page: New ACC/AHA Prevention
Guidelines: Building a Bridge to Even Stronger
Guideline CollaborationsJohn Gordon
Harold, MD,his past month, the American College of Cardiology (ACC) and the American
FAHA, MACC
President, American
College of Cardiology
Mariell Jessup,
MD, FACC, FAHA
President, American
Heart AssociationTHeart Association (AHA), in collaboration with the National Heart, Lung, andBlood Institute (NHLBI) and other specialty societies, released 4 long-awaited
guidelines focused on the assessment of cardiovascular risk, lifestyle modiﬁcations to reduce
cardiovascular risk, and management of elevated blood cholesterol and body weight in
adults. A ﬁfth guideline, which addresses hypertension, will be initiated by the AHA and
ACC in the near future.
These guidelines are based on rigorous, comprehensive, systematic evidence reviews
sponsored by the NHLBI. The ACC and AHA collaborated with professional organizations
to ﬁnalize these ACC/AHA cardiovascular prevention guidelines and stakeholder organi-
zations were invited to review and endorse the ﬁnal documents. Each guideline provides
important updated guidance for primary care providers, nurses, pharmacists, and specialty
medicine providers on how best to manage the care of patients at risk for cardiovascular-
related diseases on the basis of the latest scientiﬁc evidence.
For example, the Guideline for the Management of Overweight and Obese Adults
addresses the appropriateness of the current body mass index and waist circumference cut
points used to determine risk in overweight and obese adults across diverse populations; the
impact of weight loss on risk factors for cardiovascular disease and type 2 diabetes; optimal
behavioral and dietary intervention strategies; lifestyle treatment approaches, such as
community-based programs, for weight loss and weight-loss maintenance; and the beneﬁts
and risks of various bariatric surgical procedures.
According to the expert panel, the “information will help providers decide who should be
recommended for weight loss, and what health improvements can be expected.” However,
the panel suggests that further research into the beneﬁts of weight loss and the risks asso-
ciated with overweight and obesity is needed. In addition, the role of new weight-loss drugs,
as well as the type of patient most likely to beneﬁt from surgical interventions, is also needed,
the panel notes.
Similarly, the Guideline for Lifestyle Management to Reduce Cardiovascular Risk
provides updates to dietary and physical activity recommendations for adult patients with
high low-density lipoprotein cholesterol and/or hypertension, while the Guideline for the
Assessment of Cardiovascular Risk offers a new approach to risk assessment. According to
the expert panel responsible for the risk assessment guideline, these recommendations
represent a step forward in the prevention of atherosclerotic cardiovascular disease
(ASCVD): “The ability to estimate risk for a more broadly based ASCVD outcome that is
more relevant to contemporary populations, especially women and African Americans, and
the ability to provide risk estimates speciﬁc to African Americans, are the major advances of
this approach,” the panel notes. “Promoting lifetime risk estimation may represent an
additional step forward in supporting lifestyle behavior change counseling efforts.”
The Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults also generates important discussion around the use of statins for
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patients. The expert panel recommends statin therapy for
patients at increased ASCVD risk who are most likely to
experience a net beneﬁt in terms of the potential to reduce
ASCVD events and the potential for adverse effects. The
panel also suggests the use of statins to prevent both nonfatal
and fatal ASCVD events, an approach, the panel argues, that
can not only reduce the large burden of disability from
nonfatal stroke and nonfatal coronary heart disease events but
also reduce increasing health care costs.
The overarching goal of both the ACC and the AHA is to
prevent cardiovascular diseases and improve the care of people
living with, or at risk for, these diseases. Professional educa-
tion, research, and the development of evidence-based
guidelines, standards, and policies are at the heart of both
organizations’ efforts to achieve this goal. Given the ACC
and AHA’s long-time partnership and leadership in devel-
oping cardiovascular-related guidelines, the collaboration with
the NHLBI to complete these guidelines seemed a logical
transition. Moreover, the collaborative effort adheres to the
model recommended in a 2011 NHLBI Advisory Council
report: let the NHLBI focus on comprehensive, timely
evidence reviews and subsequently partner with organizations
to develop guideline recommendations.
As with any major change, however, transition stages are
often needed to bridge the past and the future. These
currently published guidelines are intended to be that tran-
sitional bridge. Where there were inherent differences in
grading systems and/or imperfect alignment between the
NHLBI and ACC/AHA methodological explanations,
these variations were duly noted. In addition, all recom-
mendations are included in both the current NHLBI
grading format and the AHA/ACC Class of Recommen-
dation/Level of Evidence construct, with which our
members are most familiar.In the interest of transparency, the ACC and AHA also
requested that panel authors resubmit disclosures of rela-
tionships with industry as of July 8, 2013. Any new
relationships since the respective panels did their ﬁnal
voting on their recommendations and the ACC and
AHA’s involvement in the process are disclosed in an
appendix to each document. Finally, the expert panels were
largely unable to consider evidence beyond 2011, with
a few exceptions that are noted in the documents. The
ACC and AHA recognize that new scientiﬁc research in
some of these areas has occurred since then. In fact,
planning is already under way, working with the NHLBI
and partner societies, to begin any needed updates to these
guidelines starting in early 2014.
The joint ACC/AHA Task Force on Practice Guidelines
and the Subcommittee on Prevention Guidelines should
be commended for taking on the Herculean task of
shepherding this transition, communicating the rationale
and expectations to the expert panels and partnering
organizations, and ﬁnalizing the guideline documents
expeditiously. Because of these efforts, we have laid the
groundwork for even stronger guidelines on these issues
moving into the future. Even more important, we have
created important recommendations that will serve only to
beneﬁt patients, providers, and the broader public health
as we continue to take on the nation’s number one killer:
cardiovascular disease.Address correspondence to:
John Gordon Harold, MD, FAHA, MACC
American College of Cardiology
2400 N Street NW
Washington, DC 20037
E-mail: president@acc.org
